Jurgi Camblong Sells 22,486 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• SOPHiA GENETICS Chairman Jurgi Camblong sold 22,486 shares on July 6 at an average price of $5.25, totaling about $118,052. The sale was made under a pre-arranged Rule 10b5-1 plan and was tied to tax withholding on equity award vesting.
• Camblong has been an active seller recently, including a much larger sale of 50,069 shares on June 26, along with several other transactions in April and June. After the latest sale, he still held about 3.56 million shares valued at roughly $18.68 million.
• SOPHiA GENETICS shares were trading around $5.44 on Tuesday, with the company carrying a market cap of about $456 million. The stock has ranged from $2.92 to $6.30 over the past year, and the company recently posted a quarterly earnings miss despite revenue topping estimates.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) Chairman Jurgi Camblong sold 22,486 shares of the firm's stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.25, for a total value of $118,051.50. Following the sale, the chairman directly owned 3,558,807 shares in the company, valued at approximately $18,683,736.75. This trade represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total transaction of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total transaction of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total transaction of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,552.00.

SOPHiA GENETICS Price Performance

NASDAQ SOPH traded up $0.10 during trading hours on Tuesday, reaching $5.44. The company's stock had a trading volume of 284,463 shares, compared to its average volume of 187,273. The firm has a market capitalization of $456.36 million, a price-to-earnings ratio of -10.46 and a beta of 0.96. The company's 50-day moving average is $5.12 and its two-hundred day moving average is $4.96. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. SOPHiA GENETICS SA has a 1-year low of $2.92 and a 1-year high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of SOPHiA GENETICS by 16.4% in the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock worth $682,000 after buying an additional 31,000 shares in the last quarter. Akre Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock worth $148,000 after acquiring an additional 6,205 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS during the 3rd quarter valued at about $49,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SOPH. BTIG Research reaffirmed a "buy" rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.